A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells


  • Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A information to most cancers immunotherapy: from T cell fundamental science to scientific follow. Nat. Rev. Immunol. 20, 651–668 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies—BiTEs and past. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).

    PubMed 

    Google Scholar 

  • Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in power lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sharma, P. & Allison, J. P. The way forward for immune checkpoint remedy. Science 348, 56–61 (2015).

    ADS 
    CAS 
    PubMed 

    Google Scholar 

  • Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in people responding to CD19-directed CAR T-cell remedy. Blood 128, 360–370 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

    ADS 
    CAS 
    PubMed 

    Google Scholar 

  • Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Pure innate and adaptive immunity to most cancers. Annu. Rev. Immunol. 29, 235–271 (2011).

    CAS 
    PubMed 

    Google Scholar 

  • Trabolsi, A., Arumov, A. & Schatz, J. H. T cell-activating bispecific antibodies in most cancers remedy. J. Immunol. 203, 585–592 (2019).

    CAS 
    PubMed 

    Google Scholar 

  • Wu, L. et al. Trispecific antibodies improve the therapeutic efficacy of tumor-directed T cells via T cell receptor co-stimulation. Nat. Most cancers 1, 86–98 (2020).

    PubMed 

    Google Scholar 

  • Steinmetz, A. et al. CODV-Ig, a common bispecific tetravalent and multifunctional immunoglobulin format for medical purposes. MAbs 8, 867–878 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Berchuck, A. et al. Overexpression of HER-2/neu is related to poor survival in superior epithelial ovarian most cancers. Most cancers Res. 50, 4087–4091 (1990).

    CAS 
    PubMed 

    Google Scholar 

  • Burstein, H. J. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353, 1652–1654 (2005).

    CAS 

    Google Scholar 

  • Gravalos, C. & Jimeno, A. HER2 in gastric most cancers: a brand new prognostic issue and a novel therapeutic goal. Ann. Oncol. 19, 1523–1529 (2008).

    CAS 
    PubMed 

    Google Scholar 

  • Kim, E. Ok., Kim, Ok. A., Lee, C. Y. & Shim, H. S. The frequency and scientific affect of HER2 alterations in lung adenocarcinoma. PLoS ONE 12, e0171280 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Pollock, N. I. & Grandis, J. R. HER2 as a therapeutic goal in head and neck squamous cell carcinoma. Clin. Most cancers Res. 21, 526–533 (2015).

    CAS 
    PubMed 

    Google Scholar 

  • Santin, A. D. et al. Amplification of c-erbB2 oncogene: a serious prognostic indicator in uterine serous papillary carcinoma. Most cancers 104, 1391–1397 (2005).

    CAS 
    PubMed 

    Google Scholar 

  • Siena, S. et al. Focusing on the human epidermal development issue receptor 2 (HER2) oncogene in colorectal most cancers. Ann. Oncol. 29, 1108–1119 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Slamon, D. J. et al. Human breast most cancers: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).

    ADS 
    CAS 
    PubMed 

    Google Scholar 

  • Yoon, H. H. et al. Affiliation of HER2/ErbB2 expression and gene amplification with pathologic options and prognosis in esophageal adenocarcinomas. Clin. Most cancers Res. 18, 546–554 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hicks, D. G. & Kulkarni, S. HER2+ breast most cancers: assessment of biologic relevance and optimum use of diagnostic instruments. Am. J. Clin. Pathol. 129, 263–273 (2008).

    PubMed 

    Google Scholar 

  • Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to trastuzumab in breast most cancers. Clin. Most cancers Res. 15, 7479–7491 (2009).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shak, S. Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody scientific program in HER2-overexpressing metastatic breast most cancers. Herceptin Multinational Investigator Research Group. Semin. Oncol. 26, 71–77 (1999).

    CAS 
    PubMed 

    Google Scholar 

  • Wang, J. & Xu, B. Focused therapeutic choices and future views for HER2-positive breast most cancers. Sign Transduct. Goal Ther. 4, 34 (2019).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Laux, I. et al. Response variations between human CD4(+) and CD8(+) T-cells throughout CD28 costimulation: implications for immune cell-based therapies and research associated to the enlargement of double-positive T-cells throughout getting older. Clin. Immunol. 96, 187–197 (2000).

    CAS 
    PubMed 

    Google Scholar 

  • Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and administration. Blood 127, 3321–3330 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kroschinsky, F. et al. New medication, new toxicities: extreme uncomfortable side effects of recent focused and immunotherapy of most cancers and their administration. Crit. Care 21, 89 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Saber, H., Del Valle, P., Ricks, T. Ok. & Leighton, J. Ok. An FDA oncology evaluation of CD3 bispecific constructs and first-in-human dose choice. Regul. Toxicol. Pharmacol. 90, 144–152 (2017).

    CAS 
    PubMed 

    Google Scholar 

  • Baselga, J. et al. Section II research of weekly intravenous trastuzumab (herceptin) in sufferers with HER2/neu-overexpressing metastatic breast most cancers. Semin. Oncol. 26, 78–83 (1999).

    CAS 
    PubMed 

    Google Scholar 

  • Zuch de Zafra, C. L. et al. Focusing on a number of myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine launch. Clin. Most cancers Res. 25, 3921–3933 (2019).

    CAS 
    PubMed 

    Google Scholar 

  • Harbeck, N. et al. HER2 dimerization inhibitor pertuzumab—mode of motion and scientific information in breast most cancers. Breast Care (Basel) 8, 49–55 (2013).

    Google Scholar 

  • Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the therapy of HER2+ metastatic breast most cancers. Curr. Opin. Mol. Ther. 12, 350–360 (2010).

    CAS 
    PubMed 

    Google Scholar 

  • Bang, Y. J. et al. First-in-human section 1 research of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in sufferers with HER2-positive superior strong tumors. Ann. Oncol. 28, 855–861 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jones, Ok. L. & Buzdar, A. U. Evolving novel anti-HER2 methods. Lancet Oncol. 10, 1179–1187 (2009).

    CAS 
    PubMed 

    Google Scholar 

  • Mignot, F. et al. Concurrent administration of anti-HER2 remedy and radiotherapy: systematic assessment. Radiother. Oncol. 124, 190–199 (2017).

    CAS 
    PubMed 

    Google Scholar 

  • Vu, T. & Claret, F. X. Trastuzumab: up to date mechanisms of motion and resistance in breast most cancers. Entrance. Oncol. 2, 62 (2012).

    PubMed 
    PubMed Central 

    Google Scholar 

  • Buie, L. W., Pecoraro, J. J., Horvat, T. Z. & Daley, R. J. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann. Pharmacother. 49, 1057–1067 (2015).

    CAS 
    PubMed 

    Google Scholar 

  • Tran, B. et al. 609O Outcomes from a section I research of AMG 160, a half-life prolonged (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune remedy for metastatic castration-resistant prostate most cancers (mCRPC). Ann. Oncol. 31, s507 (2020).

    Google Scholar 

  • Deegen, P. et al. The PSMA-targeting half-life prolonged BiTE remedy AMG 160 has potent antitumor exercise in preclinical fashions of metastatic castration-resistant prostate most cancers. Clin. Most cancers Res. 27, 2928–2937 (2021).

    CAS 
    PubMed 

    Google Scholar 

  • Raghu, G. et al. SAR156597 in idiopathic pulmonary fibrosis: a section 2 placebo-controlled research (DRI11772). Eur. Respir. J. 52, 1801130 (2018).

    CAS 
    PubMed 

    Google Scholar 

  • Service provider, A. M. et al. An environment friendly path to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).

    CAS 
    PubMed 

    Google Scholar 

  • Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV safety in macaques. Science 358, 85–90 (2017).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alegre, M. L. et al. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57, 1537–1543 (1994).

    CAS 
    PubMed 

    Google Scholar 

  • Smith, Ok. B. & Ellis, S. A. Standardisation of a process for quantifying floor antigens by oblique immunofluorescence. J. Immunol. Strategies 228, 29–36 (1999).

    CAS 
    PubMed 

    Google Scholar 

  • Leave a Reply